MedWatch

Niche medicine paves the way for hard-tried Biotech

Several small biotech companies have found a refuge in the generally hard-tried biotech business. If companies put their efforts into niche medicine, fewer clinical trials are needed, and at the same time the European Union backs the projects financially. Now the industry wants rare diseases put on the agenda during the Danish presidency of the EU.

Foto: Renata Horvat / Stock.xchng

It can be difficult for smaller biotech companies to compete with the capital power and R&D levels of large pharmaceutical companies. That is why an increasing number of smaller actors in the pharmaceutical industry try their hands at drugs for rare diseases, the so-called orphan drugs.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier